Gland Pharma Ltd Share Price
As on 18 November 2025 at 23:55 IST
Gland Pharma Q1 FY26 Results:
Net profit rose 50% to ₹215.5 crores, compared to ₹144 crores in Q1 FY25. Total income in Q1 FY26 increased 8% to ₹1,563 crores from ₹1,453 crores in the same period last year.
About Gland Pharma Ltd
Gland Pharma Ltd is a leading pharmaceutical company producing complex generic injectables. The company provides high-quality injectable products for various therapeutic areas, including oncology, ophthalmology, and critical care. It operates in the pharmaceutical sector. The company was founded in 1978 in Hyderabad, India, making it decades old. Gland Pharma Ltd headquarters is in Hyderabad, Telangana, India. Gland Pharma’s main products include a wide range of injectables such as liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. The company also focuses on complex injectables, including peptides, suspensions, and hormonal products. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-6.32%
Over 6 Months
22.33%
Over 1 Year
2.37%
Over 3 Years
4.63%
Gland Pharma Ltd Summary
Close ₹1,815.30
Open ₹1,818
High ₹1,838.30
Low ₹1,810.40
Volume 90,653
Net Turnover (in Cr) ₹16.58
52Wk High ₹2,131
52Wk Low ₹1,277.80
52Wk High / Low
1,277.80
2,131
Gland Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹29,908.23
EPS (TTM) 70.19
Book Value (BV) 610.02
Div. Yield 0.99 %
P/E (TTM) 25.85
Price/Book Value 2.97
Delivery % 72.11 %
Face Value 1
Key Ratios
PE Ratio 24.07
PB Ratio 2.69
EV to Sales 5.78
PEG Ratio 5.44
ROA 11.14
ROE 11.62
Debt-Equity -
Net Profit Margin 26.47
Operating Profit Margin 40.27
Gland Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 5,830.11 | 5,834.96 | 3,865.06 | 4,624.65 | 3,597.65 |
| Total Expenses | 4,767.45 | 4,702.41 | 2,754.02 | 3,006.09 | 2,262.84 |
| Profit Before Tax | 1,062.66 | 1,132.54 | 1,054.58 | 1,618.55 | 1,334.81 |
| Profit After Tax | 698.53 | 772.46 | 781.04 | 1,211.66 | 996.96 |
| Operating Profit After Depreciation | 1,104.66 | 1,158.74 | 1,118.49 | 1,623.79 | 1,338.22 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,147.23 | 3,946.75 | 1,570.55 | 1,512.19 | 954.23 |
| Total Non Current Assets | 4,441.98 | 5,016.09 | 1,876.73 | 1,981.54 | 1,372.44 |
| Total Current Assets | 6,782.94 | 5,645.15 | 6,900.81 | 5,852.08 | 5,123.64 |
| Total Assets | 11,224.92 | 10,661.25 | 8,777.53 | 7,833.62 | 6,496.08 |
| Total Shareholder's Fund | 9,150.74 | 8,723.84 | 7,958.72 | 7,157.62 | 5,903.24 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 914.73 | 996.80 | 363.97 | 790.77 | 604.93 |
| Net Cash Used In Investing Activities | 1,717.87 | -1,749.19 | 1,211.19 | -999.31 | -1,520.42 |
| Net Cash Used In Financing Activities | -433.48 | -799.42 | 14.92 | 34.90 | 1,238.46 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,331.22 | 4,334.09 | 3,856.99 | 4,624.65 | 3,597.65 |
| Total Expenses | 2,865.64 | 2,928.60 | 2,752.13 | 3,005.61 | 2,262.80 |
| Profit Before Tax | 1,465.59 | 1,405.50 | 1,048.40 | 1,619.04 | 1,334.85 |
| Profit After Tax | 1,089.75 | 1,043.33 | 775.83 | 1,212.15 | 997 |
| Operating Profit After Depreciation | 1,488.42 | 1,413.34 | 1,112.28 | 1,624.28 | 1,338.26 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,744.99 | 1,693.73 | 1,570.55 | 1,512.19 | 954.23 |
| Total Non Current Assets | 4,654.65 | 4,969.76 | 1,884.84 | 1,989.70 | 1,372.99 |
| Total Current Assets | 5,766.96 | 4,571.32 | 6,888.34 | 5,844.44 | 5,123.07 |
| Total Assets | 10,421.62 | 9,541.09 | 8,773.18 | 7,834.14 | 6,496.06 |
| Total Shareholder's Fund | 9,755.10 | 8,995.29 | 7,953.30 | 7,158.23 | 5,903.28 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,073.67 | 1,135.97 | 367.89 | 791.29 | 604.93 |
| Net Cash Used In Investing Activities | 1,582.29 | -2,917.58 | 1,211.22 | -1,006.92 | -1,520.97 |
| Net Cash Used In Financing Activities | -339.54 | -7.40 | 14.92 | 34.90 | 1,238.46 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,486.88 | 1,505.62 | 1,424.91 | 1,384.05 | 1,405.83 |
| Total Expenses | 1,172.99 | 1,137.86 | 1,077.40 | 1,024.09 | 1,108.77 |
| Profit Before Tax | 283.92 | 312.74 | 288.33 | 299.30 | 256.78 |
| Profit After Tax | 183.68 | 215.48 | 186.54 | 204.69 | 163.53 |
| Operating Profit after Depreciation | 398.05 | 425.29 | 391.54 | 418.45 | 356.72 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,074.15 | 1,038.84 | 1,030.35 | 1,010.78 | 1,062.99 |
| Total Expenses | 699.26 | 679.99 | 636.23 | 619.64 | 699.19 |
| Profit Before Tax | 408.67 | 362.38 | 391.32 | 394.12 | 379.81 |
| Profit After Tax | 302 | 269.26 | 290 | 295.12 | 281.71 |
| Operating Profit after Depreciation | 457.48 | 413.59 | 437.84 | 456.20 | 421.60 |
Gland Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,804.37
S2 1,793.43
S3 1,776.47
Pivot 1,821.33
R1 1,832.27
R2 1,849.23
R3 1,860.17
Moving Average
20 SMA 1,895.42
50 SMA 1,934.41
100 SMA 1,931.79
200 SMA 1,733.41
Gland Pharma Ltd Corporate Actions
Gland Pharma Ltd
₹18.0/Share
Announcement Date 14 Aug 2025
Record Date 14 Aug 2025
Div Yield 1800%
Gland Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Gland Pharma Ltd Top Mutal Funds Invested
Gland Pharma Ltd News
Gland Pharma schedules board meeting
On 3 November 2025
18 Oct 2025, 11:03 am
Gland Pharma Ltd spurts 1.55%, rises for third straight session
Gland Pharma Ltd is quoting at Rs 1915.3, up 1.55% on the day as on 12:49 IST on the NSE. The stock is up 0.49% in last one year as compared to a 0.9% fall in NIFTY and a 5.14% fall in the Nifty Pharma index.
05 Sep 2025, 01:05 pm
Gland Pharma receives USFDA nod for Vasopressin in 5% Dextrose RTU injection
Gland Pharma announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Vasopressin in 5% Dextrose injection, (0.4 Units/mL) RTU vials.
26 Aug 2025, 01:11 pm
Gland Pharma receives USFDA approval for Vasopressin in 5% Dextrose RTU Injection
26 Aug 2025, 12:35 pm
Gland Pharma gains after Q1 PAT climbs 50% YoY to Rs 215 cr
Gland Pharma advanced 1.36% to Rs 1,991.15 after the company's consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25.
06 Aug 2025, 12:45 pm
Gland Pharma Ltd Stock Analysis
- Annual revenue for Gland Pharma Ltd decreased by 0.07% to ₹4,331.22 crore in FY 2025 from ₹4,334.09 crore in FY 2024.
- Annual Net Profit for Gland Pharma Ltd increased by 4.45% to ₹1,089.75 crore in FY 2025 from ₹1,043.33 crore in FY 2024.
- Promoter Shareholding in Gland Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 51.83% in June 2025 to 51.83% in September 2025.
- Gland Pharma Ltd delivered a 1-year return of 2.37% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Gland Pharma Ltd share price moved down by 0.78% from its previous close of INR ₹1,815.30. The latest Gland Pharma Ltd share price is INR ₹1,801.20.
- Gland Pharma Ltd share price today has been at a low of 1,795.20 and a high of 1,828.10. Over the past 52 weeks, the Gland Pharma Ltd share price has seen a low of 1,277.80 and a high of 2,131.
About Gland Pharma Ltd
Gland Pharma Ltd is a leading pharmaceutical company producing complex generic injectables. The company provides high-quality injectable products across various therapeutic areas. These include oncology, ophthalmology, and critical care. Gland Pharma primarily operates under a business-to-business (B2B) model. It supplies its products to global markets.
Gland Pharma operates in the pharmaceutical sector. It has established itself as a significant player in the industry. The company was founded in 1978 making it decades old. It is now one of the largest and fastest-growing generic injectables companies with a global footprint.
Gland Pharma Ltd's headquarters is in Hyderabad, Telangana, India. The promoters of the company include Fosun Pharma Industrial Pte. Ltd with a significant 51.83% stake in the company. A team of professional managerial promoters manages the operations of the company. These include-
While Gland Pharma is a significant player in the generic injectables sector, it is not the largest in terms of market share. It also falls short in market capitalization. However, it holds a strong position in its niche market. This is particularly true for its manufacturing of complex injectables. This leadership is a testament to the company’s expertise and dedication to quality and innovation. The registered office of Gland Pharma Ltd is in Hyderabad, Telangana, and the registrar's office is in Mumbai, Maharashtra.
One of the primary impacts of Gland Pharma is its role in improving healthcare outcomes. The company’s high-quality injectable products are essential for treating various medical conditions. These include cancer, infections, and chronic diseases. These products are used in hospitals and healthcare facilities worldwide. They ensure that patients receive adequate and reliable treatments. Gland Pharma’s commitment to quality and safety ensures its products meet stringent regulatory standards. This gives healthcare professionals the confidence to use them in critical care settings.
Gland Pharma’s impact extends to the global pharmaceutical supply chain. The company operates under a business-to-business (B2B) model. It supplies its products to pharmaceutical companies and healthcare providers worldwide. This model allows Gland Pharma to reach various markets. These include the United States, Europe, Canada, Australia, and India.
The company’s focus on complex injectables has positioned it as a leader in the pharmaceutical industry. Gland Pharma specializes in producing a wide range of injectable products. These include liquid vials, lyophilized vials, pre-filled syringes, ampoules, and bags. These products are essential for various therapeutic areas. These include oncology, ophthalmology, and critical care.
Gland Pharma’s impact is also evident in its contributions to economic growth. The company provides employment opportunities to thousands of people. This supports livelihoods and contributes to economic development. Gland Pharma’s operations have a positive ripple effect on the communities where it operates, fostering economic growth and stability.
Innovation is a critical component of Gland Pharma’s impact. The company invests heavily in research and development to create advanced injectable products. These products are designed to meet the market's evolving needs. Gland Pharma’s focus on innovation ensures that it remains competitive and continues to offer solutions that enhance the performance and efficiency of its clients. The company’s R&D efforts focus on developing new formulations. They also aim to improve manufacturing processes. The company focuses on creating advanced solutions that cater to diverse applications.
Gland Pharma’s commitment to sustainability is another important aspect of its impact. The company recognizes the importance of environmental responsibility and is committed to reducing its environmental footprint. Gland Pharma focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste, reduce energy consumption, and use environmentally friendly materials.
The company’s strong leadership and management team have been instrumental in its success. Gland Pharma’s management team is committed to maintaining its reputation for quality and innovation, ensuring its continued success in the market.
Gland Pharma also engages in various corporate social responsibility initiatives. These initiatives aim to improve community health, education, and well-being. The company’s initiatives include supporting healthcare facilities, promoting environmental sustainability, and providing student scholarships. Gland Pharma’s focus on social responsibility reflects its belief that businesses have a role in creating a better world.
Gland Pharma operates in the pharmaceutical sector. It has established itself as a significant player in the industry. The company was founded in 1978 making it decades old. It is now one of the largest and fastest-growing generic injectables companies with a global footprint.
Gland Pharma Ltd's headquarters is in Hyderabad, Telangana, India. The promoters of the company include Fosun Pharma Industrial Pte. Ltd with a significant 51.83% stake in the company. A team of professional managerial promoters manages the operations of the company. These include-
- Yiu Kwan Stanley Lau
- Srinivas Sadu
- Yao Fang
- Jia Ai (Allen) Zhang
- Qiyu Chen
While Gland Pharma is a significant player in the generic injectables sector, it is not the largest in terms of market share. It also falls short in market capitalization. However, it holds a strong position in its niche market. This is particularly true for its manufacturing of complex injectables. This leadership is a testament to the company’s expertise and dedication to quality and innovation. The registered office of Gland Pharma Ltd is in Hyderabad, Telangana, and the registrar's office is in Mumbai, Maharashtra.
Impact of Gland Pharma Limited
Gland Pharma Ltd has made a significant impact on the pharmaceutical industry. This is especially true in the field of generic injectables. Established in 1978, the company has become one of the largest manufacturers of complex injectables. It serves global markets. The importance of Gland Pharma is evident in its contributions to healthcare and economic growth. It also plays a significant role in innovation.One of the primary impacts of Gland Pharma is its role in improving healthcare outcomes. The company’s high-quality injectable products are essential for treating various medical conditions. These include cancer, infections, and chronic diseases. These products are used in hospitals and healthcare facilities worldwide. They ensure that patients receive adequate and reliable treatments. Gland Pharma’s commitment to quality and safety ensures its products meet stringent regulatory standards. This gives healthcare professionals the confidence to use them in critical care settings.
Gland Pharma’s impact extends to the global pharmaceutical supply chain. The company operates under a business-to-business (B2B) model. It supplies its products to pharmaceutical companies and healthcare providers worldwide. This model allows Gland Pharma to reach various markets. These include the United States, Europe, Canada, Australia, and India.
The company’s focus on complex injectables has positioned it as a leader in the pharmaceutical industry. Gland Pharma specializes in producing a wide range of injectable products. These include liquid vials, lyophilized vials, pre-filled syringes, ampoules, and bags. These products are essential for various therapeutic areas. These include oncology, ophthalmology, and critical care.
Gland Pharma’s impact is also evident in its contributions to economic growth. The company provides employment opportunities to thousands of people. This supports livelihoods and contributes to economic development. Gland Pharma’s operations have a positive ripple effect on the communities where it operates, fostering economic growth and stability.
Innovation is a critical component of Gland Pharma’s impact. The company invests heavily in research and development to create advanced injectable products. These products are designed to meet the market's evolving needs. Gland Pharma’s focus on innovation ensures that it remains competitive and continues to offer solutions that enhance the performance and efficiency of its clients. The company’s R&D efforts focus on developing new formulations. They also aim to improve manufacturing processes. The company focuses on creating advanced solutions that cater to diverse applications.
Gland Pharma’s commitment to sustainability is another important aspect of its impact. The company recognizes the importance of environmental responsibility and is committed to reducing its environmental footprint. Gland Pharma focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste, reduce energy consumption, and use environmentally friendly materials.
The company’s strong leadership and management team have been instrumental in its success. Gland Pharma’s management team is committed to maintaining its reputation for quality and innovation, ensuring its continued success in the market.
Gland Pharma also engages in various corporate social responsibility initiatives. These initiatives aim to improve community health, education, and well-being. The company’s initiatives include supporting healthcare facilities, promoting environmental sustainability, and providing student scholarships. Gland Pharma’s focus on social responsibility reflects its belief that businesses have a role in creating a better world.
FAQ’s
What is the share price of Gland Pharma Ltd today?
Gland Pharma Ltd share price as on 18 Nov 2025 is ₹ 1801.2
What is the Market Cap of Gland Pharma Ltd?
The market cap of Gland Pharma Ltd stock is ₹29,908.23 Cr.
What is the PE Ratio of Gland Pharma Ltd?
The Price to Earnings (P/E) Ratio of Gland Pharma Ltd is 24.07
What is the PB Ratio of Gland Pharma Ltd?
The Price to Book (P/B) Ratio of Gland Pharma Ltd is 2.69
What is the 52 week high of Gland Pharma Ltd Share Price?
The 52 week high of Gland Pharma Ltd share price stands at ₹2,131
What is the 52 week low of Gland Pharma Ltd Share Price?
The 52 week low of Gland Pharma Ltd share price stands at ₹1,277.80
How can I buy shares of Gland Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Gland Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
